search
Back to results

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Primary Purpose

Parkinson Disease, Tremor

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
Suvecaltamide
Sponsored by
Jazz Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring Suvecaltamide, Moderate tremor, Severe tremor, Parkinson's disease, JZP385, Residual tremor, T-type calcium channels, Movement disorders, Tremor, Parkinson's disease tremor

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male and female participants ages 40 to 80 years inclusive, at the time of signing the informed consent form (ICF). Body mass index from 17 to 45 kg/m2 (inclusive) at screening. Diagnosis of clinically probable or clinically established idiopathic Parkinson's disease (PD) meeting the Movement Disorder Society (MDS) 2015 criteria within the past 5 years. Participants must be individually optimized on PD medications for the treatment of other cardinal signs of PD (bradykinesia, rigidity) per the judgment of the investigator. Optimized treatment is defined as the maximum therapeutic effect obtained with PD medications when no further improvement is expected regardless of any additional adjustments to these medications or when the PD medications or adjustments to these medications are anticipated to result in intolerable side effects. This will be based on the investigator's clinical judgment. Participants must be on a stable dosing regimen of their permitted PD and/or other tremor (eg, propranolol) medications for the treatment of motor symptoms for at least 6 weeks prior to screening and do not anticipate the need to make any changes for the duration of the study. A lack of use of medications used to treat motor symptoms also must be stable for 6 weeks prior to screening and remain stable for the duration of the study (eg, participants who tried PD medications and are no longer taking them must be off of these medications and stable for 6 weeks prior to screening). For participants who experience motor fluctuations, tremor must also be present during "ON" periods and participants should be able to have tremor symptoms evaluated during "ON" periods, as determined by the investigator, in relation to the participant's PD medications. If necessary, participants may take their PD medications in the clinic during visits where tremor symptoms are evaluated (timing of PD medications relative to tremor evaluations can be determined by the investigator). Participants have moderate to severe impairment associated with tremor at both the screening and baseline visits, as determined by all the following: A score of > 21 on The Essential Tremor Assessment Rating Scale, Activities of Daily Living (TETRAS-ADL) subscale; and A score of > 2 for at least 1 hand on item 6 (ie, 6a and/or 6b) of The Essential Tremor Assessment Rating Scale, Performance Subscale (TETRAS-PS). Note: The TETRAS-PS is rated by a blinded and trained rater on-site; and Clinician Global Impression of Severity (CGI-S) rating of tremor severity of > 2 (at least moderate for participant's ability to function). Contraception: During the study intervention and for at least 30 days after the last dose of study intervention male participants must refrain from donating sperm. All non-abstinent male participants must agree to use a male condom when engaging in any activity that allows for the passage of ejaculate to another person. Non-abstinent male participants with female partners must agree to use the male condom in combination with the female partner's use of a highly effective contraceptive method with a failure rate of < 1% per year. Female participants must not be pregnant or breastfeeding, are either women of non-childbearing potential (WONCBP), or are women of childbearing potential (WOCBP) using a highly effective contraceptive method with a failure rate of < 1% during the study intervention period and for at least 30 days after the last dose of study intervention. Male partners of WOCBP are required to use barrier protection, eg, condoms, during the study intervention period and for at least 30 days after the last dose of study intervention. A WOCBP must have a negative highly sensitive serum pregnancy test at Screening Visit 1 and negative urine pregnancy tests (unless serum is required by local regulations) at the baseline visit. - If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. Exclusion Criteria: Medical Conditions Known history or current evidence of other medical or neurological conditions that may cause or explain the participant's tremor in the opinion of the investigator. Hoehn & Yahr stage 5 (confinement to bed or wheelchair unless aided). Participants who only experience tremor during their "OFF" periods. Severity of motor fluctuations or medication-induced dyskinesia that would interfere with the assessment of tremor and/or "ON"/"OFF" periods that are unpredictable per the opinion of the investigator. Clinically significant symptomatic orthostatic hypotension in the opinion of the investigator. Has evidence at screening of cognitive impairment as defined by a Montreal Cognitive Assessment (MoCA) score < 22 or has a cognitive impairment that in the opinion of the investigator would prevent completion of study procedures or the ability to provide informed consent. History or presence of bipolar and related mood disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Current suicidal risk as determined from history, by presence of active suicidal ideation as indicated by positive response to item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) (within the past 24 months, or any history of suicide attempt; current or past (within 1 year) major depressive episode according to DSM-5 criteria. History (within past 2 years at screening) or presence of substance use disorder (including alcohol) according to DSM-5 criteria, known drug dependence, or seeking treatment for alcohol or substance abuse-related disorder. Nicotine use disorder would not be exclusionary if it does not impact tremor per the judgment of the investigator. Prior/Concomitant Therapy Treatment-naïve patients (ie, those who have never tried PD medication) are excluded from participating in the study. As needed (PRN) use of medication/substance(s) that might interfere with the evaluation of tremor on study visit days, such as, but not limited to, stimulant decongestants, beta-agonist bronchodilators, benzodiazepine, sedative/hypnotics, and alcohol. Participants who consume caffeine or use tobacco should take their regular amount of caffeine or tobacco on clinic days. Prior or planned surgical intervention to treat PD, including but not limited to magnetic resonance-guided focused ultrasound thalamotomy, deep brain stimulation, ablative thalamotomy, and gamma knife thalamotomy. A history of implantation of an infusion pump for delivery of PD medications, or percutaneous endoscopic gastrojejunostomy for delivery of PD medications including levodopa-carbidopa intestinal gel would not be exclusionary if these medication delivery systems are no longer being utilized. Inability to refrain from using a mechanical device for the management of tremor (eg, weighted bracelet) during the study. Botulinum toxin injection in the 6 months before screening or planned use at any time during the study. Currently taking dopamine antagonists or depleting medications. Use of prescription or nonprescription drugs or other products (eg, St. John's Wort) known to be inducers of cytochrome 3A4 (CYP3A4) (cause > 30% reduction of sensitive substrates area under the plasma concentration-time curve [AUC]), which cannot be discontinued at least 4 weeks before baseline, or planned use at any time during the study. Use of prescription or nonprescription drugs or other products (eg, grapefruit) known to be strong or moderate inhibitors of CYP3A4, which cannot be discontinued 2 weeks or 5 half-lives, whichever is longer, before baseline, or planned use at any time during the study. Use of proton pump inhibitors, which cannot be discontinued at least 2 weeks before baseline, or planned use at any time during the study. (Occasional use of antacids or histamine receptor type 2 [H2] receptor antagonists will be permitted, but antacids should be taken at least 4 hours apart from study intervention; H2 receptor antagonists should be taken at least 4 hours after and/or 12 hours before study intervention). Other Exclusions Daily or near-daily use of more than 2 units of alcohol per day. A unit of alcohol is defined as a 12-fluid ounce (350 mL) glass of beer (5% alcohol by volume), a 5-fluid ounce (150 mL) glass of wine (12% alcohol by volume), or a 1.5-fluid ounce (44 mL)glass of spirit (40% alcohol by volume). Regular consumption of > 600 mg caffeine per day or > 6 cups of coffee per day.

Sites / Locations

  • Movement Disorders Center of ArizonaRecruiting
  • Woodland Research NorthwestRecruiting
  • Keck School of Medicine of University of Southern California (USC)Recruiting
  • Neurology of Central Florida Research Center LLCRecruiting
  • Parkinson's Disease And Movement Disorder Center Of Boca RatonRecruiting
  • USF Parkinson's Disease and Movement Disorders CenterRecruiting
  • NeuroTrials Research Inc.Recruiting
  • Hawaii Pacific NeuroscienceRecruiting
  • Northwestern Medical Group, Department of NeurologyRecruiting
  • University of Kansas Medical CenterRecruiting
  • The Nene and Jamie Koch Comprehensive Movement Disorders CenterRecruiting
  • Albany Medical CollegeRecruiting
  • Dent Neurologic InstituteRecruiting
  • South Shore Neurologic Associates PCRecruiting
  • University of Cincinnati
  • Veracity Neuroscience LLCRecruiting
  • Texas Movement Disorder Specialist, PLLCRecruiting
  • Central Texas Neurology ConsultantsRecruiting
  • Inova Parkinson's and Movement Disorders Center - AlexandriaRecruiting
  • Inova NeurologyRecruiting
  • EvergreenHealth Neuroscience InstituteRecruiting
  • NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSISRecruiting
  • Centrum Medyczne PlejadyRecruiting
  • Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. i M. Nastaj Spólka PartnerskaRecruiting
  • Gabinety Lekarskie Rivermed Sp. z o.o.Recruiting
  • Hospital Universitario CrucesRecruiting
  • Hospital Ramón y CajalRecruiting
  • Hospital Universitario Virgen MacarenaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

Sulvecaltamide

Arm Description

Participants who will receive a matching placebo during the Dose Titration, Optimization Period, and Maintenance Period.

Participants who will receive an optimal dose of suvecaltamide during the Dose Titration, Optimization Period, and Maintenance Period.

Outcomes

Primary Outcome Measures

Change from Baseline to Week 17 on the Essential Tremor Rating Scale (TETRAS) Composite Outcome Score
The TETRAS composite outcome score is the sum of modified items 1 - 11 of the TETRAS-ADL subscale and modified items 6 - 7 of the TETRAS-PS. The TETRAS-ADL subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as eating, drinking, dressing, and other fine motor skills. The TETRAS-PS is a clinical rating scale that quantifies tremor in the head, face voice, limbs and trunk. Items 6 (drawing an Archimedes spiral using left and right hands) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 3, with 0 representing normal or slightly abnormal and 3 representing severely abnormal. The sum of the 14 items provides the TETRAS composite outcome score, which ranges from 0 - 42, with higher scores representing more severe tremor.

Secondary Outcome Measures

Proportion of Participants Who Improved (≥ 1-point improvement) from Baseline to Week 17 on the Clinical Global Impression of Severity (CGI-S)
The CGI-S is a 5-point Likert-type rating scale assessed by qualified personnel to assess the severity of the impact of tremor in PD on the participants' ability to function. The responses to this investigator-completed scale range from 1 (no limitations) to 5 (severe), with higher scores indicating a worse outcome.
Change from Baseline to Week 17 on The Essential Tremor Rating Scale, Activities of Daily Living Subscale (TETRAS-ADL)
The TETRAS-ADL subscale is a patient-rated scale of the impact of tremor on day-to-day functioning administered by a trained interviewer. The TETRAS-ADL subscale directly measures how a patient functions by assessing activities impacted by tremor, such as eating and drinking, dressing and personal hygiene, carrying items, and fine motor skills. The TETRAS-ADL has 12 items and each item is rated on a 0 (normal) to 4 (severe) scale, with higher scores representing more severe tremor.
Change from Baseline to Week 17 on The Essential Tremor Rating Scale, Performance Subscale (TETRAS-PS)
The TETRAS-PS is a clinical rating scale performed by a blinded rater that quantifies tremor in the head, face, voice, limbs, and trunk. Each item will be rated on a scale of 0 (normal) to 4 (severe). The sum of the individual scores provides the overall score, ranging from 0 to 64, with higher scores representing more severe tremor.
Change from Baseline to Week 17 on TETRAS total score (TETRAS-ADL + TETRAS-PS)
The TETRAS total score is the sum of the scores of the full TETRAS-ADL and TETRAS-PS subscales. Each item is rated on a 0 (normal) to 4 (severe) scale, and total scores range from 0 to 112, with higher scores representing more severe tremor. The TETRAS-PS is performed by a blinded rater.
Proportion of participants who improved (≥ 1 point) from Baseline to Week 17 on the Patient's Global Impression of Severity (PGI-S)
The PGI-S is a 5-point Likert-type rating scale, with response options ranging from 1 (no limitations) to 5 (severe), with higher scores indicating a worse outcome. The participant will rate his/her impression of the severity of the impact of their tremor in PD on their current ability to function.
Proportion of participants who were much improved on the Patient's Global Impression of Change (PGI-C) at Week 17
The PGI-C is a 5-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to tremor since baseline. The responses to this scale range from 1 (Much improved) to 5 (Much worse), with higher scores indicating a worse outcome.
Proportion of Participants who were Much Improved on the Clinician's Global Impression of Change (CGI-C) at Week 17
The CGI-C is a 5-point Likert-type rating scale that a qualified medical personnel will use to rate the change in severity of the participants' ability to function due to their tremor since baseline. The responses to this scale range from 1 (Much improved) to 5 (Much worse), with higher scores indicating a worse outcome.
Change from Baseline to Week 17 on the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Tremor Score
The tremor items from the MDS-UPDRS consist of 1 item from Part II (Item 2.10) and 10 items from Part III (Items 3.15a,b, 3.16a,b, 3.17a-e, and 3.18). These items are graded on a severity score of 0 to 4 (normal, slight, mild, moderate, severe). Item 2.10 assesses the patient report of the presence of tremor and impact on daily activities. Items 3.15, 3.16, and 3.17 are clinician assessments of the amplitude of distinct types of tremor (resting, postural, and kinetic respectively)in the right and left upper extremities separately. Item 3.17 also includes separate clinician assessments for both lower extremities and for the lip/jaw. Item 3.18 provides a clinician assessment of the constancy of rest tremor without regard to anatomical location. For the 11 individual assessments the maximum possible total score of these tremor items is 44, with higher scores indicating more

Full Information

First Posted
November 30, 2022
Last Updated
August 28, 2023
Sponsor
Jazz Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT05642442
Brief Title
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Official Title
A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants With Parkinson's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2022 (Actual)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jazz Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tasks.
Detailed Description
Participants will be randomized 1:1 to receive suvecaltamide or placebo and stratified by the Essential Tremor Rating Scale (TETRAS) composite outcome score (≤ 17 or > 17) as assessed at baseline. The maximum total duration of the study for each participant will be 23 weeks, with a maximum treatment duration of 17 weeks. For each participant, the study consists of a Screening Period (up to 4 weeks), a 5-week Dose Titration and Optimization Period, a 12-week Maintenance Period, and a 2-week Safety Follow-up Period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease, Tremor
Keywords
Suvecaltamide, Moderate tremor, Severe tremor, Parkinson's disease, JZP385, Residual tremor, T-type calcium channels, Movement disorders, Tremor, Parkinson's disease tremor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants who will receive a matching placebo during the Dose Titration, Optimization Period, and Maintenance Period.
Arm Title
Sulvecaltamide
Arm Type
Experimental
Arm Description
Participants who will receive an optimal dose of suvecaltamide during the Dose Titration, Optimization Period, and Maintenance Period.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matching placebo capsule(s) administered every day (QD) orally. Titration may proceed at a rate of 1 matching placebo capsule per day every 7 days as required for optimal efficacy and tolerability up to a maximum number of 3 matching placebo capsules per day.
Intervention Type
Drug
Intervention Name(s)
Suvecaltamide
Other Intervention Name(s)
JZP385, CX-8998, MK-8998
Intervention Description
Suvecaltamide capsule administered every day (QD) orally. Titration may proceed at a rate of 10 mg suvecaltamide per day every 7 days as required for optimal efficacy and tolerability up to a maximum dose of 30 mg suvecaltamide per day.
Primary Outcome Measure Information:
Title
Change from Baseline to Week 17 on the Essential Tremor Rating Scale (TETRAS) Composite Outcome Score
Description
The TETRAS composite outcome score is the sum of modified items 1 - 11 of the TETRAS-ADL subscale and modified items 6 - 7 of the TETRAS-PS. The TETRAS-ADL subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as eating, drinking, dressing, and other fine motor skills. The TETRAS-PS is a clinical rating scale that quantifies tremor in the head, face voice, limbs and trunk. Items 6 (drawing an Archimedes spiral using left and right hands) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 3, with 0 representing normal or slightly abnormal and 3 representing severely abnormal. The sum of the 14 items provides the TETRAS composite outcome score, which ranges from 0 - 42, with higher scores representing more severe tremor.
Time Frame
Baseline to Week 17 post-dose.
Secondary Outcome Measure Information:
Title
Proportion of Participants Who Improved (≥ 1-point improvement) from Baseline to Week 17 on the Clinical Global Impression of Severity (CGI-S)
Description
The CGI-S is a 5-point Likert-type rating scale assessed by qualified personnel to assess the severity of the impact of tremor in PD on the participants' ability to function. The responses to this investigator-completed scale range from 1 (no limitations) to 5 (severe), with higher scores indicating a worse outcome.
Time Frame
Baseline to Week 17 post-dose.
Title
Change from Baseline to Week 17 on The Essential Tremor Rating Scale, Activities of Daily Living Subscale (TETRAS-ADL)
Description
The TETRAS-ADL subscale is a patient-rated scale of the impact of tremor on day-to-day functioning administered by a trained interviewer. The TETRAS-ADL subscale directly measures how a patient functions by assessing activities impacted by tremor, such as eating and drinking, dressing and personal hygiene, carrying items, and fine motor skills. The TETRAS-ADL has 12 items and each item is rated on a 0 (normal) to 4 (severe) scale, with higher scores representing more severe tremor.
Time Frame
Baseline to Week 17 post-dose.
Title
Change from Baseline to Week 17 on The Essential Tremor Rating Scale, Performance Subscale (TETRAS-PS)
Description
The TETRAS-PS is a clinical rating scale performed by a blinded rater that quantifies tremor in the head, face, voice, limbs, and trunk. Each item will be rated on a scale of 0 (normal) to 4 (severe). The sum of the individual scores provides the overall score, ranging from 0 to 64, with higher scores representing more severe tremor.
Time Frame
Baseline to Week 17 post-dose.
Title
Change from Baseline to Week 17 on TETRAS total score (TETRAS-ADL + TETRAS-PS)
Description
The TETRAS total score is the sum of the scores of the full TETRAS-ADL and TETRAS-PS subscales. Each item is rated on a 0 (normal) to 4 (severe) scale, and total scores range from 0 to 112, with higher scores representing more severe tremor. The TETRAS-PS is performed by a blinded rater.
Time Frame
Baseline to Week 17 post-dose.
Title
Proportion of participants who improved (≥ 1 point) from Baseline to Week 17 on the Patient's Global Impression of Severity (PGI-S)
Description
The PGI-S is a 5-point Likert-type rating scale, with response options ranging from 1 (no limitations) to 5 (severe), with higher scores indicating a worse outcome. The participant will rate his/her impression of the severity of the impact of their tremor in PD on their current ability to function.
Time Frame
Baseline to Week 17 post-dose.
Title
Proportion of participants who were much improved on the Patient's Global Impression of Change (PGI-C) at Week 17
Description
The PGI-C is a 5-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to tremor since baseline. The responses to this scale range from 1 (Much improved) to 5 (Much worse), with higher scores indicating a worse outcome.
Time Frame
Week 17 post-dose.
Title
Proportion of Participants who were Much Improved on the Clinician's Global Impression of Change (CGI-C) at Week 17
Description
The CGI-C is a 5-point Likert-type rating scale that a qualified medical personnel will use to rate the change in severity of the participants' ability to function due to their tremor since baseline. The responses to this scale range from 1 (Much improved) to 5 (Much worse), with higher scores indicating a worse outcome.
Time Frame
Week 17 post-dose.
Title
Change from Baseline to Week 17 on the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Tremor Score
Description
The tremor items from the MDS-UPDRS consist of 1 item from Part II (Item 2.10) and 10 items from Part III (Items 3.15a,b, 3.16a,b, 3.17a-e, and 3.18). These items are graded on a severity score of 0 to 4 (normal, slight, mild, moderate, severe). Item 2.10 assesses the patient report of the presence of tremor and impact on daily activities. Items 3.15, 3.16, and 3.17 are clinician assessments of the amplitude of distinct types of tremor (resting, postural, and kinetic respectively)in the right and left upper extremities separately. Item 3.17 also includes separate clinician assessments for both lower extremities and for the lip/jaw. Item 3.18 provides a clinician assessment of the constancy of rest tremor without regard to anatomical location. For the 11 individual assessments the maximum possible total score of these tremor items is 44, with higher scores indicating more
Time Frame
Baseline to Week 17 post-dose.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female participants ages 40 to 80 years inclusive, at the time of signing the informed consent form (ICF). Body mass index from 17 to 45 kg/m2 (inclusive) at screening. Diagnosis of clinically probable or clinically established idiopathic Parkinson's disease (PD) meeting the Movement Disorder Society (MDS) 2015 criteria within the past 5 years. Participants must be individually optimized on PD medications for the treatment of other cardinal signs of PD (bradykinesia, rigidity) per the judgment of the investigator. Optimized treatment is defined as the maximum therapeutic effect obtained with PD medications when no further improvement is expected regardless of any additional adjustments to these medications or when the PD medications or adjustments to these medications are anticipated to result in intolerable side effects. This will be based on the investigator's clinical judgment. Participants must be on a stable dosing regimen of their permitted PD and/or other tremor (eg, propranolol) medications for the treatment of motor symptoms for at least 6 weeks prior to screening and do not anticipate the need to make any changes for the duration of the study. A lack of use of medications used to treat motor symptoms also must be stable for 6 weeks prior to screening and remain stable for the duration of the study (eg, participants who tried PD medications and are no longer taking them must be off of these medications and stable for 6 weeks prior to screening). For participants who experience motor fluctuations, tremor must also be present during "ON" periods and participants should be able to have tremor symptoms evaluated during "ON" periods, as determined by the investigator, in relation to the participant's PD medications. If necessary, participants may take their PD medications in the clinic during visits where tremor symptoms are evaluated (timing of PD medications relative to tremor evaluations can be determined by the investigator). Participants have moderate to severe impairment associated with tremor at both the screening and baseline visits, as determined by all the following: A score of > 21 on The Essential Tremor Assessment Rating Scale, Activities of Daily Living (TETRAS-ADL) subscale; and A score of > 2 for at least 1 hand on item 6 (ie, 6a and/or 6b) of The Essential Tremor Assessment Rating Scale, Performance Subscale (TETRAS-PS). Note: The TETRAS-PS is rated by a blinded and trained rater on-site; and Clinician Global Impression of Severity (CGI-S) rating of tremor severity of > 2 (at least moderate for participant's ability to function). Contraception: During the study intervention and for at least 30 days after the last dose of study intervention male participants must refrain from donating sperm. All non-abstinent male participants must agree to use a male condom when engaging in any activity that allows for the passage of ejaculate to another person. Non-abstinent male participants with female partners must agree to use the male condom in combination with the female partner's use of a highly effective contraceptive method with a failure rate of < 1% per year. Female participants must not be pregnant or breastfeeding, are either women of non-childbearing potential (WONCBP), or are women of childbearing potential (WOCBP) using a highly effective contraceptive method with a failure rate of < 1% during the study intervention period and for at least 30 days after the last dose of study intervention. Male partners of WOCBP are required to use barrier protection, eg, condoms, during the study intervention period and for at least 30 days after the last dose of study intervention. A WOCBP must have a negative highly sensitive serum pregnancy test at Screening Visit 1 and negative urine pregnancy tests (unless serum is required by local regulations) at the baseline visit. - If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. Exclusion Criteria: Medical Conditions Known history or current evidence of other medical or neurological conditions that may cause or explain the participant's tremor in the opinion of the investigator. Hoehn & Yahr stage 5 (confinement to bed or wheelchair unless aided). Participants who only experience tremor during their "OFF" periods. Severity of motor fluctuations or medication-induced dyskinesia that would interfere with the assessment of tremor and/or "ON"/"OFF" periods that are unpredictable per the opinion of the investigator. Clinically significant symptomatic orthostatic hypotension in the opinion of the investigator. Has evidence at screening of cognitive impairment as defined by a Montreal Cognitive Assessment (MoCA) score < 22 or has a cognitive impairment that in the opinion of the investigator would prevent completion of study procedures or the ability to provide informed consent. History or presence of bipolar and related mood disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Current suicidal risk as determined from history, by presence of active suicidal ideation as indicated by positive response to item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) (within the past 24 months, or any history of suicide attempt; current or past (within 1 year) major depressive episode according to DSM-5 criteria. History (within past 2 years at screening) or presence of substance use disorder (including alcohol) according to DSM-5 criteria, known drug dependence, or seeking treatment for alcohol or substance abuse-related disorder. Nicotine use disorder would not be exclusionary if it does not impact tremor per the judgment of the investigator. Prior/Concomitant Therapy Treatment-naïve patients (ie, those who have never tried PD medication) are excluded from participating in the study. As needed (PRN) use of medication/substance(s) that might interfere with the evaluation of tremor on study visit days, such as, but not limited to, stimulant decongestants, beta-agonist bronchodilators, benzodiazepine, sedative/hypnotics, and alcohol. Participants who consume caffeine or use tobacco should take their regular amount of caffeine or tobacco on clinic days. Prior or planned surgical intervention to treat PD, including but not limited to magnetic resonance-guided focused ultrasound thalamotomy, deep brain stimulation, ablative thalamotomy, and gamma knife thalamotomy. A history of implantation of an infusion pump for delivery of PD medications, or percutaneous endoscopic gastrojejunostomy for delivery of PD medications including levodopa-carbidopa intestinal gel would not be exclusionary if these medication delivery systems are no longer being utilized. Inability to refrain from using a mechanical device for the management of tremor (eg, weighted bracelet) during the study. Botulinum toxin injection in the 6 months before screening or planned use at any time during the study. Currently taking dopamine antagonists or depleting medications. Use of prescription or nonprescription drugs or other products (eg, St. John's Wort) known to be inducers of cytochrome 3A4 (CYP3A4) (cause > 30% reduction of sensitive substrates area under the plasma concentration-time curve [AUC]), which cannot be discontinued at least 4 weeks before baseline, or planned use at any time during the study. Use of prescription or nonprescription drugs or other products (eg, grapefruit) known to be strong or moderate inhibitors of CYP3A4, which cannot be discontinued 2 weeks or 5 half-lives, whichever is longer, before baseline, or planned use at any time during the study. Use of proton pump inhibitors, which cannot be discontinued at least 2 weeks before baseline, or planned use at any time during the study. (Occasional use of antacids or histamine receptor type 2 [H2] receptor antagonists will be permitted, but antacids should be taken at least 4 hours apart from study intervention; H2 receptor antagonists should be taken at least 4 hours after and/or 12 hours before study intervention). Other Exclusions Daily or near-daily use of more than 2 units of alcohol per day. A unit of alcohol is defined as a 12-fluid ounce (350 mL) glass of beer (5% alcohol by volume), a 5-fluid ounce (150 mL) glass of wine (12% alcohol by volume), or a 1.5-fluid ounce (44 mL)glass of spirit (40% alcohol by volume). Regular consumption of > 600 mg caffeine per day or > 6 cups of coffee per day.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Clinical Trial Disclosure & Transparency
Phone
215-832-3750
Email
ClinicalTrialDisclosure@JazzPharma.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jazz Study Director
Organizational Affiliation
Jazz Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Movement Disorders Center of Arizona
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
480-526-5441
Facility Name
Woodland Research Northwest
City
Rogers
State/Province
Arkansas
ZIP/Postal Code
72758
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
479-927-3000
Facility Name
Keck School of Medicine of University of Southern California (USC)
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
323-442-7218
Facility Name
Neurology of Central Florida Research Center LLC
City
Altamonte Springs
State/Province
Florida
ZIP/Postal Code
32714
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
407-790-4990
Facility Name
Parkinson's Disease And Movement Disorder Center Of Boca Raton
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
561-392-1818
Facility Name
USF Parkinson's Disease and Movement Disorders Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
813-396-0606
Facility Name
NeuroTrials Research Inc.
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30328
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
404-851-9934
Facility Name
Hawaii Pacific Neuroscience
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96817
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
808-564-6141
Facility Name
Northwestern Medical Group, Department of Neurology
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
312-503-8216
Facility Name
University of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
913-588-5000
Facility Name
The Nene and Jamie Koch Comprehensive Movement Disorders Center
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87106
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
505-272-3199
Facility Name
Albany Medical College
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
518-262-3125
Facility Name
Dent Neurologic Institute
City
Amherst
State/Province
New York
ZIP/Postal Code
14226
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
716-819-4117
Facility Name
South Shore Neurologic Associates PC
City
Patchogue
State/Province
New York
ZIP/Postal Code
11772
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
631-758-1910
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45221
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
513-475-8730
Facility Name
Veracity Neuroscience LLC
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38157
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
901-443-9170
Facility Name
Texas Movement Disorder Specialist, PLLC
City
Georgetown
State/Province
Texas
ZIP/Postal Code
78628
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
512-693-4041
Facility Name
Central Texas Neurology Consultants
City
Round Rock
State/Province
Texas
ZIP/Postal Code
78681
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
512-218-1222
Facility Name
Inova Parkinson's and Movement Disorders Center - Alexandria
City
Alexandria
State/Province
Virginia
ZIP/Postal Code
22311
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
703-845-1500
Facility Name
Inova Neurology
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
703-205-2147
Facility Name
EvergreenHealth Neuroscience Institute
City
Kirkland
State/Province
Washington
ZIP/Postal Code
98034
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
425-899-3123
Facility Name
NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS
City
Katowice
ZIP/Postal Code
40-123
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
+48 602 643 90
Facility Name
Centrum Medyczne Plejady
City
Kraków
ZIP/Postal Code
30-363
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
+48 691 776 505
Facility Name
Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. i M. Nastaj Spólka Partnerska
City
Lublin
ZIP/Postal Code
20-064
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
+48 81 464 42 21
Facility Name
Gabinety Lekarskie Rivermed Sp. z o.o.
City
Poznań
ZIP/Postal Code
61-441
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
+48 889427070
Facility Name
Hospital Universitario Cruces
City
Barakaldo
ZIP/Postal Code
48903
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
+34 638 974 687
Facility Name
Hospital Ramón y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
+34 678463623
Facility Name
Hospital Universitario Virgen Macarena
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
+34 955006627

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

We'll reach out to this number within 24 hrs